All In Biotech

Drug Trial Radar · NCT07004972

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

A Phase 4, Single-Arm, Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy in India

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Sep 4, 2025

Primary completion

Dec 13, 2027

Study completion Dec 13, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and effectiveness of mavacamten in adults with obstructive hypertrophic cardiomyopathy in India.

Conditions

  • Symptomatic Obstructive Hypertrophic Cardiomyopathy

Interventions

  • MavacamtenDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of serious Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Week 48

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0014

    Hyderabad, Andhra Pradesh, India

  • Local Institution - 0011

    Ahmedabad, Gujarat, India

  • Local Institution - 0006

    Surat, Gujarat, India

  • Local Institution - 0020

    Gurgaon, Haryana, India

  • Medanta Heart Institute

    Gurgaon, Haryana, India

  • Local Institution - 0004

    Belagavi, Karnataka, India

  • Local Institution - 0008

    Mangalore, Karnataka, India

  • Local Institution - 0002

    Ernākulam, Kerala, India

  • Local Institution - 0001

    Kottayam, Kerala, India

  • Local Institution - 0012

    Chhatrapati Sambhajinagar, Maharashtra, India

  • Local Institution - 0025

    Mumbai, Maharashtra, India

  • Local Institution - 0025

    Mumbai, Maharashtra, India

  • Local Institution - 0013

    Nagpur, Maharashtra, India

  • Local Institution - 0019

    Nagpur, Maharashtra, India

  • Local Institution - 0024

    Nagpur, Maharashtra, India

  • Local Institution - 0010

    Pune, Maharashtra, India

  • Local Institution - 0021

    New Delhi, National Capital Territory of Delhi, India

  • Local Institution - 0005

    New Delhi, National Capital Territory of Delhi, India

  • Local Institution - 0007

    Bikaner, Rajasthan, India

  • Local Institution - 0003

    Chennai, Tamil Nadu, India

  • Local Institution - 0022

    Aligarh, Uttar Pradesh, India

  • Laxmipat Singhania Institute of Cardiology

    Kanpur, Uttar Pradesh, India

  • Local Institution - 0023

    Kanpur, Uttar Pradesh, India

  • Local Institution - 0017

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.